BioNTech's Oncology Ambitions Confront Tariff and Trial Turbulence

BioNTech stock faces pressure as it shifts from COVID vaccines to cancer drugs. New partnerships and promising data are offset by clinical setbacks, U.S. tariffs, and a looming leadership change.

BioNTech SE is navigating a complex transition, with its share price reflecting the growing pains of shifting from a pandemic-era vaccine leader to a fully-fledged oncology biotech. The stock, trading around €77.90, sits roughly 26% below its 52-week high, pressured by a confluence of clinical uncertainties, new U.S. tariffs, and a looming leadership change.

The company's strategic pivot is most evident in its expanding cancer pipeline, now bolstered by a new alliance. BioNTech has entered a partnership with Boehringer Ingelheim targeting advanced small-cell lung cancer. The collaboration plans a Phase-Ib/II study combining experimental therapies from both firms. This adds to a robust lung cancer portfolio that now encompasses 16 ongoing trials, including four pivotal Phase 3 studies. Data for BioNTech's candidate pumitamig has shown promise, with an objective response rate exceeding 76% in a Phase II trial. Patient dosing in the Boehringer study is slated to begin in the second half of 2026.

However, the path forward is fraught with challenges. Recent clinical updates have injected volatility. While the oncology candidate gotistobart demonstrated a 54% reduction in mortality risk compared to chemotherapy in a Phase 1 study, it was also associated with a higher rate of severe side effects. This has fueled analyst skepticism about its prospects in crucial late-stage testing. Separately, a Phase 3 trial for a COVID-19 booster, required by the U.S. FDA, was discontinued due to insufficient participant enrollment.

Political headwinds are also mounting. The U.S. administration's imposition of tariffs of up to 100% on patented pharmaceutical imports presents a new risk, though the rules include exemptions for companies manufacturing domestically or lowering prices. For BioNTech, its established U.S. production infrastructure with partner Pfizer for Comirnaty offers some mitigation. The specific 15% tariff on European pharmaceutical products, set to take effect in late September 2026, will apply, though cell and gene therapies are initially exempt.

This operational and political turbulence is reshaping Wall Street's view. Analysts have been actively adjusting their price targets, reflecting divided opinions on the company's near-term trajectory. Leerink Partners made one of the more bearish moves, cutting its target to $94 from $113, citing diminished prospects for gotistobart. BMO Capital lowered its target to $128, expressing concern over the planned departure of CEO U?ur ?ahin and CMO Özlem Türeci. H.C. Wainwright reduced its target to $130 following Phase 2 data for pumitamig.

Other firms maintain a more constructive stance. Clear Street, while lowering its target to $167, and Wells Fargo, holding its target at $150, both retain Buy ratings on the stock. The search for a new CEO is seen by some, including Leerink, as a potential positive catalyst for the share price.

Financially, BioNTech is undertaking this costly transformation from a position of significant strength. The company forecasts 2026 revenue will decline to a range of €2.0 to €2.3 billion, while research and development expenses are projected to climb as high as €2.5 billion. This means current investment is outstripping income. A substantial cash reserve of approximately €17.2 billion provides the long-term security to fund this strategic shift.

Governance changes are advancing to support the new focus. The upcoming virtual Annual General Meeting on May 15 is set to formally expand the Supervisory Board with two new members, bringing critical expertise in oncology and clinical development. This move is designed to bolster oversight of the company's 15 ongoing Phase 3 studies in cancer.

With shares down approximately 5.5% year-to-date, investor patience is being tested. The coming months will be critical as BioNTech works to solidify its leadership, advance its clinical programs, and navigate an increasingly complex geopolitical landscape for global biopharma.